Jack Lu, Director of Corporate Development, joined us on the Water Tower Hour podcast to discuss the business and platform priorities. We focused on AI Nose technology and opportunities in healthcare and beyond. Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Link is accessible in our full report. Ainos business and priorities. The medtech company has three key technology platforms: (1) AI Nose point of care testing (POCT); (2) Low dose interferon-a Vel...
Enrolled first subject in feline oral disease study, paving way for animal health opportunity. The randomized, double-blind Veldona animal study will enroll 30 cats with feline chronic gingivostomatitis (FCGS) at a single Taiwan clinical site. Two dosage groups, a low dose (6,000 IU) and high dose (12,000 IU), will be evaluated. The first enrolled subject will be dosed later this week. Ainos expects to complete enrollment by year-end, with data in 1Q25. Positive results would support a pivotal f...
Diversified medtech and therapeutics company. Ainos develops AI-powered point-of-care testing (POCT) devices to detect diseases and other health conditions, in addition to a low-dose interferon-a (IFN-a) therapeutic for infectious and autoimmune diseases. AI Nose enables portable, fast, and convenient POCT. Ainos utilizes electronic nose (E-nose) technology and a proprietary AI algorithm to recognize and distinguish between different digital smell patterns of volatile organic compounds (VOCs) em...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.